by John Hewitt | Aug 13, 2024 | Blog
The ATP binding site of kinases represents both a golden opportunity and a formidable challenge for drug discovery teams. This well-defined pocket serves as the docking site for potent small-molecule inhibitors, making it an attractive target for drug development....
by John Hewitt | Apr 12, 2023 | News
~ New Data will be Presented on the Company’s Innovative Assay Technologies, Preclinical Profiling Models and Proprietary Screening Platforms ~ ~ Reaction Biology will be at Booth #1527 in the AACR 2023 Exhibit Hall ~ Malvern, PA – April 12, 2023 – Reaction Biology...
by John Hewitt | Dec 19, 2022 | News
Malvern, PA, December 19, 2022 – Reaction Biology Corporation (“Reaction”), an industry-leading provider of drug discovery services, today announced that it has been selected to participate as a Specialized Center in the Chemical Biology Consortium (CBC), the...
by John Hewitt | Dec 2, 2022 | News
~ Bioassay GmbH, an Independent Contract Laboratory, Specializes in the Development, Validation and Routine Performance of Bioanalytical Assays ~ ~ Transaction Includes Acquisition of Bioassay GmbH Subsidiary, Peptide Specialty Laboratories GmbH, a Provider...
by John Hewitt | Nov 3, 2022 | News
~ Reaction Biology Acquires the Hershey, Pennsylvania-Based U.S. Operations of Vyant Bio Subsidiary vivoPharm PTY Ltd ~ ~ Transaction Expands Reaction Biology’s Capabilities to Provide Customers with Solutions in Both the Discovery and Development of New Drug...
